NO20044698L - Statinterapi for a oke kognitiv opprettholdelse - Google Patents
Statinterapi for a oke kognitiv opprettholdelseInfo
- Publication number
- NO20044698L NO20044698L NO20044698A NO20044698A NO20044698L NO 20044698 L NO20044698 L NO 20044698L NO 20044698 A NO20044698 A NO 20044698A NO 20044698 A NO20044698 A NO 20044698A NO 20044698 L NO20044698 L NO 20044698L
- Authority
- NO
- Norway
- Prior art keywords
- statin
- statin therapy
- increase cognitive
- galantamine
- active ingredient
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 3
- 230000001149 cognitive effect Effects 0.000 title 1
- 238000012423 maintenance Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 abstract 4
- 206010012289 Dementia Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 229960003980 galantamine Drugs 0.000 abstract 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36928502P | 2002-04-02 | 2002-04-02 | |
| PCT/EP2003/003324 WO2003082298A1 (en) | 2002-04-02 | 2003-03-28 | Statin therapy for enhancing cognitive maintenance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20044698L true NO20044698L (no) | 2004-10-29 |
Family
ID=28675573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20044698A NO20044698L (no) | 2002-04-02 | 2004-10-29 | Statinterapi for a oke kognitiv opprettholdelse |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1492539B1 (da) |
| JP (1) | JP2005525391A (da) |
| KR (1) | KR100986194B1 (da) |
| CN (1) | CN100528164C (da) |
| AT (1) | ATE331523T1 (da) |
| AU (1) | AU2003226753B2 (da) |
| BR (1) | BR0308293A (da) |
| CA (1) | CA2480275C (da) |
| CY (1) | CY1105545T1 (da) |
| DE (1) | DE60306503T2 (da) |
| DK (1) | DK1492539T3 (da) |
| EA (1) | EA013069B1 (da) |
| ES (1) | ES2268393T3 (da) |
| HK (1) | HK1079688A1 (da) |
| IL (2) | IL164317A0 (da) |
| MX (1) | MXPA04009535A (da) |
| NO (1) | NO20044698L (da) |
| NZ (1) | NZ536111A (da) |
| PL (1) | PL211160B1 (da) |
| PT (1) | PT1492539E (da) |
| UA (1) | UA79605C2 (da) |
| WO (1) | WO2003082298A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1603548A4 (en) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS |
| AU2005232447A1 (en) * | 2004-04-14 | 2005-10-27 | Warner-Lambert Company Llc | Therapeutic combination for treatment of Alzheimers disease |
| WO2005123068A2 (en) * | 2004-06-08 | 2005-12-29 | Axonyx, Inc. | Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor |
| GB0607946D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| AU2007299726A1 (en) * | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis |
| TWI432195B (zh) | 2007-10-03 | 2014-04-01 | Kowa Co | 神經細胞死亡抑制劑 |
| US20160303146A1 (en) * | 2013-12-13 | 2016-10-20 | David A. TABACZYNSKI | Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders |
-
2003
- 2003-03-28 EA EA200401295A patent/EA013069B1/ru not_active IP Right Cessation
- 2003-03-28 PT PT03745196T patent/PT1492539E/pt unknown
- 2003-03-28 PL PL371551A patent/PL211160B1/pl unknown
- 2003-03-28 WO PCT/EP2003/003324 patent/WO2003082298A1/en active IP Right Grant
- 2003-03-28 JP JP2003579835A patent/JP2005525391A/ja active Pending
- 2003-03-28 IL IL16431703A patent/IL164317A0/xx unknown
- 2003-03-28 BR BR0308293-8A patent/BR0308293A/pt not_active IP Right Cessation
- 2003-03-28 KR KR1020047013127A patent/KR100986194B1/ko active IP Right Grant
- 2003-03-28 NZ NZ536111A patent/NZ536111A/xx not_active IP Right Cessation
- 2003-03-28 CA CA2480275A patent/CA2480275C/en not_active Expired - Fee Related
- 2003-03-28 EP EP03745196A patent/EP1492539B1/en not_active Expired - Lifetime
- 2003-03-28 UA UA20040806803A patent/UA79605C2/uk unknown
- 2003-03-28 ES ES03745196T patent/ES2268393T3/es not_active Expired - Lifetime
- 2003-03-28 DK DK03745196T patent/DK1492539T3/da active
- 2003-03-28 MX MXPA04009535A patent/MXPA04009535A/es active IP Right Grant
- 2003-03-28 CN CNB038073854A patent/CN100528164C/zh not_active Expired - Fee Related
- 2003-03-28 AT AT03745196T patent/ATE331523T1/de active
- 2003-03-28 AU AU2003226753A patent/AU2003226753B2/en not_active Ceased
- 2003-03-28 DE DE60306503T patent/DE60306503T2/de not_active Expired - Lifetime
-
2004
- 2004-09-28 IL IL164317A patent/IL164317A/en not_active IP Right Cessation
- 2004-10-29 NO NO20044698A patent/NO20044698L/no not_active Application Discontinuation
-
2005
- 2005-12-21 HK HK05111808.4A patent/HK1079688A1/xx not_active IP Right Cessation
-
2006
- 2006-09-27 CY CY20061101397T patent/CY1105545T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ536111A (en) | 2006-03-31 |
| CA2480275C (en) | 2011-08-16 |
| HK1079688A1 (en) | 2006-04-13 |
| CY1105545T1 (el) | 2010-07-28 |
| WO2003082298A1 (en) | 2003-10-09 |
| EP1492539B1 (en) | 2006-06-28 |
| JP2005525391A (ja) | 2005-08-25 |
| DE60306503T2 (de) | 2007-06-21 |
| MXPA04009535A (es) | 2005-01-25 |
| AU2003226753B2 (en) | 2007-06-28 |
| PT1492539E (pt) | 2006-11-30 |
| PL371551A1 (en) | 2005-06-27 |
| KR100986194B1 (ko) | 2010-10-07 |
| CN100528164C (zh) | 2009-08-19 |
| IL164317A (en) | 2010-04-29 |
| EA013069B1 (ru) | 2010-02-26 |
| CN1642555A (zh) | 2005-07-20 |
| EA200401295A1 (ru) | 2005-02-24 |
| KR20040096608A (ko) | 2004-11-16 |
| AU2003226753A1 (en) | 2003-10-13 |
| CA2480275A1 (en) | 2003-10-09 |
| ES2268393T3 (es) | 2007-03-16 |
| DK1492539T3 (da) | 2006-10-30 |
| ATE331523T1 (de) | 2006-07-15 |
| DE60306503D1 (de) | 2006-08-10 |
| IL164317A0 (en) | 2005-12-18 |
| BR0308293A (pt) | 2004-12-28 |
| EP1492539A1 (en) | 2005-01-05 |
| UA79605C2 (en) | 2007-07-10 |
| PL211160B1 (pl) | 2012-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20053077L (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
| WO2001054681A8 (en) | Composition for treatment of stress | |
| NO20092874L (no) | Forhindring og behandling av amyloidogen sykdom | |
| RU94027680A (ru) | Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы | |
| BG101118A (en) | Therapeutical compounds | |
| ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| ATE273693T1 (de) | Proteinhaltige arzneimittel | |
| ATE231852T1 (de) | Bicyclische aromatische verbindungen | |
| NZ328874A (en) | Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders | |
| HK1079688A1 (en) | Statin product for enhancing cognitive maintenance | |
| FR2755965B1 (fr) | Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations | |
| NO20006337L (no) | Diarylselenidforbindelser og deres anvendelse i human- eller veterinærmedisin og i kosmetikk | |
| NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser | |
| Lobo et al. | Use of Theraflex-TMJ topical cream for the treatment of temporomandibular joint and muscle pain | |
| ATE404192T1 (de) | Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration | |
| ATE555787T1 (de) | Behandlungseffekte von überschüssigen reaktiven sauerstoffspezies | |
| ATE293445T1 (de) | Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel | |
| RU94032792A (ru) | Применение 5нтiа - антагонистов для прекращения использования табака | |
| DK0707477T3 (da) | Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo | |
| DE69434002D1 (de) | 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis | |
| EP0402208A1 (fr) | Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique | |
| ATE404519T1 (de) | Hyperforinderivate, ihre verwendung sowie diese enthaltende zubereitungen | |
| DE60126504D1 (de) | Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |